DK0777495T3 - Stabile, vandige alfa-inteferonopløsningsformuleringer - Google Patents

Stabile, vandige alfa-inteferonopløsningsformuleringer

Info

Publication number: DK0777495T3
Authority: DK; Denmark
Prior art keywords: interferon; alfa; stable aqueous; solution formulations; interferon solution
Prior art date: 1994-10-11

Application number

DK95935151T

Other languages

Danish (da)

English (en)

Inventor

Pui-Ho C Yuen

Douglas F Kline

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-10-11

Filing date

1995-10-10

Publication date

2000-11-06

1995-10-10 Application filed by Schering Corp filed Critical Schering Corp

2000-11-06 Application granted granted Critical

2000-11-06 Publication of DK0777495T3 publication Critical patent/DK0777495T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Virology (AREA)
Dermatology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

DK95935151T 1994-10-11 1995-10-10 Stabile, vandige alfa-inteferonopløsningsformuleringer DK0777495T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/329,813 US5766582A (en)	1994-10-11	1994-10-11	Stable, aqueous alfa interferon solution formulations
PCT/US1995/012362 WO1996011018A1 (en)	1994-10-11	1995-10-10	Stable, aqueous alfa interferon solution formulations

Publications (1)

Publication Number	Publication Date
DK0777495T3 true DK0777495T3 (da)	2000-11-06

Family

ID=23287133

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK95935151T DK0777495T3 (da)	1994-10-11	1995-10-10	Stabile, vandige alfa-inteferonopløsningsformuleringer

Country Status (24)

Country	Link
US (2)	US5766582A (fi)
EP (2)	EP0970703B1 (fi)
JP (2)	JP3978228B2 (fi)
KR (1)	KR100401401B1 (fi)
CN (1)	CN1102408C (fi)
AT (2)	ATE245033T1 (fi)
AU (1)	AU708337B2 (fi)
BR (1)	BR9509313A (fi)
CA (1)	CA2201749C (fi)
CZ (1)	CZ296961B6 (fi)
DE (2)	DE69531314T2 (fi)
DK (1)	DK0777495T3 (fi)
ES (2)	ES2198830T3 (fi)
FI (2)	FI116558B (fi)
GR (1)	GR3034619T3 (fi)
HU (1)	HU225494B1 (fi)
NO (1)	NO320604B1 (fi)
NZ (1)	NZ294464A (fi)
PL (1)	PL183797B1 (fi)
PT (1)	PT777495E (fi)
RU (1)	RU2157236C2 (fi)
SK (1)	SK282949B6 (fi)
UA (1)	UA42028C2 (fi)
WO (1)	WO1996011018A1 (fi)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030190307A1 (en)	1996-12-24	2003-10-09	Biogen, Inc.	Stable liquid interferon formulations
WO1999048535A1 (en) *	1998-03-26	1999-09-30	Schering Corporation	Formulations for protection of peg-interferon alpha conjugates
US6180096B1 (en)	1998-03-26	2001-01-30	Schering Corporation	Formulations for protection of peg-interferon alpha conjugates
BR9910505A (pt)	1998-05-15	2001-01-02	Schering Corp	Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c
US6281337B1 (en)	1998-11-12	2001-08-28	Schering Corporation	Methods for conversion of protein isoforms
SI1129111T1 (sl)	1998-11-12	2009-06-30	Schering Corp	Postopki za pretvorbo interferonskih izooblik in proizvodi le-teh
US7402559B2 (en) *	1999-03-24	2008-07-22	Msh Pharma, Incorporated	Composition and method of treatment for urogenital conditions
ATE296638T1 (de) *	1999-04-08	2005-06-15	Schering Corp	Behandlung von nierenzellen-karzinom
US6605273B2 (en)	1999-04-08	2003-08-12	Schering Corporation	Renal cell carcinoma treatment
HU230057B1 (hu)	1999-04-08	2015-06-29	Merck Sharp & Dohme Corp.	Melanóma-kezelés
US6923966B2 (en)	1999-04-08	2005-08-02	Schering Corporation	Melanoma therapy
US6362162B1 (en)	1999-04-08	2002-03-26	Schering Corporation	CML Therapy
PL203797B1 (pl)	1999-04-09	2009-11-30	Ortho Mcneil Pharm Inc	Kompozycje farmaceutyczne erytropoetyny
KR100399156B1 (ko) *	1999-11-19	2003-09-26	주식회사 엘지생명과학	α-인터페론의 용액제형
CN1175901C (zh) *	1999-12-06	2004-11-17	天津华立达生物工程有限公司	一种稳定的干扰素水溶液
AU783246C (en) *	1999-12-14	2007-03-15	Asahi Kasei Kabushiki Kaisha	Stabilizing diluent for polypeptides and antigens
JP4536194B2 (ja) *	2000-02-17	2010-09-01	大日本住友製薬株式会社	安定な注射用製剤
CN1245215C (zh)	2001-02-28	2006-03-15	四川省生物工程研究中心	重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
MXPA03009121A (es) *	2001-04-04	2004-11-22	Johnson & Johnson	Dispositivo de suministro de electrotransporte transdermico que incluye una composicion de reserva compatible antimicrobiana.
WO2002083165A1 (fr) *	2001-04-10	2002-10-24	Sumitomo Pharmaceuticals Co., Ltd.	Preparations stables destinees a etre injectees
LT4947B (lt)	2001-09-26	2002-08-26	Biotechnologijos Institutas	Interferono alfa farmacinė kompozicija
US20050232899A1 (en) *	2002-05-31	2005-10-20	Aradigm Corporation	Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US6830744B2 (en) *	2002-05-31	2004-12-14	Aradigm Corporation	Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
RU2238758C2 (ru) *	2002-07-24	2004-10-27	Закрытое акционерное общество "Вектор-Медика"	Водный раствор интерферона-альфа-два человека для инъекций
US20040053895A1 (en) *	2002-09-18	2004-03-18	Bone Care International, Inc.	Multi-use vessels for vitamin D formulations
US7148211B2 (en) *	2002-09-18	2006-12-12	Genzyme Corporation	Formulation for lipophilic agents
US20040058895A1 (en) *	2002-09-18	2004-03-25	Bone Care International, Inc.	Multi-use vessels for vitamin D formulations
US20040175359A1 (en) *	2002-11-12	2004-09-09	Desjarlais John Rudolph	Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
US7585647B2 (en)	2003-08-28	2009-09-08	Guangwen Wei	Nucleic acid encoding recombinant interferon
BRPI0507159A (pt) *	2004-02-02	2007-06-26	Ambrx Inc	polipeptìdeos em feixe de quatro hélices humanos modificados e seus usos
CN1724567B (zh) *	2004-07-22	2010-08-18	北京三元基因工程有限公司	一种稳定的重组人干扰素α1b水溶液
DE602005022895D1 (de)	2004-08-12	2010-09-23	Schering Corp	Stabile pegylierte interferon-formulierung
US20060204474A1 (en) *	2005-02-25	2006-09-14	Coroneo Minas T	Treatment of epithelial layer lesions
RU2294372C1 (ru) *	2005-06-16	2007-02-27	ООО "Цитокин"	СПОСОБ ПОЛУЧЕНИЯ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА АЛЬФА-2b И ИНТЕРФЕРОНСОДЕРЖАЩИЙ ПРЕПАРАТ (ВАРИАНТЫ)
ES2302402B1 (es)	2005-06-16	2009-05-08	Proyecto De Biomedicina Cima, S.L.	Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
CU23432B6 (es) *	2005-11-02	2009-10-16	Ct Ingenieria Genetica Biotech	Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
US8679472B1 (en)	2006-10-05	2014-03-25	Merck, Sharp & Dohme Corp.	Crystal of human interferon alpha 2B in complex with zinc
WO2008137471A2 (en)	2007-05-02	2008-11-13	Ambrx, Inc.	Modified interferon beta polypeptides and their uses
CA2702637A1 (en) *	2007-10-22	2009-04-30	Schering Corporation	Fully human anti-vegf antibodies and methods of using
US20110184379A1 (en) *	2008-03-27	2011-07-28	Medtronic, Inc.	Method and system to define patient specific therapeutic regimens by means of pharmacokinetic and pharmacodynamic tools
BRPI0915093A2 (pt)	2008-06-13	2015-10-27	Proyecto Biomedicina Cima Sl	conjugados para a administração de compostos biologicamente ativos
HUE068164T2 (hu)	2008-10-17	2024-12-28	Sanofi Aventis Deutschland	Egy inzulin és egy GLP-1 agonista kombinációja
SG10201500871TA (en)	2009-11-13	2015-04-29	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist and methionine
KR101303388B1 (ko)	2010-10-26	2013-09-03	한미사이언스 주식회사	지속형 인터페론 알파 결합체의 액상 제제
BR112013032188A2 (pt)	2011-06-23	2016-12-20	Digna Biotech Sl	composição, produto e método para tratar pacientes com hepatite c crônica
CN104768569A (zh)	2012-10-26	2015-07-08	鲁平有限公司	具有PEG干扰素α-2b的稳定的药物组合物
ES2709339T3 (es)	2013-04-03	2019-04-16	Sanofi Sa	Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de acción prolongada
US9388239B2 (en)	2014-05-01	2016-07-12	Consejo Nacional De Investigation Cientifica	Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
ES2524516B1 (es) *	2014-05-29	2015-03-31	Grifols Worldwide Operations Limited	Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
CN107073080A (zh) *	2014-09-23	2017-08-18	豪夫迈·罗氏有限公司	包含α‑型干扰素的稳定的不含苄醇的水溶液制剂
TWI758239B (zh)	2014-12-12	2022-03-21	德商賽諾菲阿凡提斯德意志有限公司	甘精胰島素/利司那肽固定比率配製劑
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
MA45276A (fr) *	2015-06-18	2018-04-25	Sage Therapeutics Inc	Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
RU2623050C2 (ru) *	2015-12-03	2017-06-21	Виталий Эдуардович Боровиков	Раствор хондроитина сульфата для внутримышечного введения и способ его получения
KR200492470Y1 (ko)	2020-03-26	2020-10-21	사공탁	빌라 주택용 쓰레기 수거함
RU2768656C1 (ru) *	2021-09-10	2022-03-24	Илья Александрович Марков	Противовирусное средство в жидкой форме и способ его приготовления
CN113797318B (zh) *	2021-10-26	2023-06-30	深圳科兴药业有限公司	一种干扰素组合物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0082481B2 (en) *	1981-12-23	1990-09-12	Schering Corporation	Stabilised alpha-interferon formulations and their preparation
JPS59176216A (ja) *	1983-03-28	1984-10-05	Sumitomo Chem Co Ltd	有用なインタ−フエロン製剤
US4680175A (en) *	1984-02-07	1987-07-14	Interferon Sciences, Inc.	Interferon administration vehicles
JPS60243028A (ja) *	1984-04-28	1985-12-03	Kyowa Hakko Kogyo Co Ltd	インタ−フエロンの可溶化方法
US4606917A (en) *	1984-10-03	1986-08-19	Syntex (U.S.A) Inc.	Synergistic antiviral composition
US4857316A (en) *	1984-10-03	1989-08-15	Syntex (U.S.A.) Inc.	Synergistic antiviral composition
JPS61277633A (ja) *	1985-05-31	1986-12-08	Toray Ind Inc	インタ−フエロン組成物
US4847079A (en) *	1985-07-29	1989-07-11	Schering Corporation	Biologically stable interferon compositions comprising thimerosal
EP0284249A1 (en) *	1987-03-13	1988-09-28	Interferon Sciences, Inc.	Lyophilized lymphokine composition
US4950652A (en) *	1987-03-23	1990-08-21	Hem Research, Inc.	dsRNAs for combination therapy in the treatment of viral diseases
US5266310A (en) *	1987-09-17	1993-11-30	Boehringer Ingelheim International Gmbh	Stabilization of therapeutically active proteins in pharmaceutical preparations
IL88233A (en) *	1987-11-03	1993-08-18	Genentech Inc	Gamma interferon formulation
DE4126983A1 (de) *	1991-08-15	1993-02-18	Boehringer Mannheim Gmbh	Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
JP3292894B2 (ja) *	1993-05-12	2002-06-17	日本電信電話株式会社	集積化受光回路

1994
- 1994-10-11 US US08/329,813 patent/US5766582A/en not_active Expired - Lifetime
1995
- 1995-10-10 ES ES99119434T patent/ES2198830T3/es not_active Expired - Lifetime
- 1995-10-10 JP JP51260696A patent/JP3978228B2/ja not_active Expired - Lifetime
- 1995-10-10 SK SK439-97A patent/SK282949B6/sk not_active IP Right Cessation
- 1995-10-10 EP EP99119434A patent/EP0970703B1/en not_active Expired - Lifetime
- 1995-10-10 ES ES95935151T patent/ES2148568T3/es not_active Expired - Lifetime
- 1995-10-10 DE DE69531314T patent/DE69531314T2/de not_active Expired - Lifetime
- 1995-10-10 WO PCT/US1995/012362 patent/WO1996011018A1/en not_active Ceased
- 1995-10-10 CZ CZ0110497A patent/CZ296961B6/cs not_active IP Right Cessation
- 1995-10-10 AT AT99119434T patent/ATE245033T1/de not_active IP Right Cessation
- 1995-10-10 HU HU9702262A patent/HU225494B1/hu unknown
- 1995-10-10 KR KR1019970702346A patent/KR100401401B1/ko not_active Expired - Lifetime
- 1995-10-10 CA CA002201749A patent/CA2201749C/en not_active Expired - Lifetime
- 1995-10-10 PL PL95319603A patent/PL183797B1/pl unknown
- 1995-10-10 AU AU37279/95A patent/AU708337B2/en not_active Expired
- 1995-10-10 PT PT95935151T patent/PT777495E/pt unknown
- 1995-10-10 CN CN95195600A patent/CN1102408C/zh not_active Expired - Lifetime
- 1995-10-10 RU RU97107611/14A patent/RU2157236C2/ru active
- 1995-10-10 AT AT95935151T patent/ATE194774T1/de active
- 1995-10-10 EP EP95935151A patent/EP0777495B1/en not_active Expired - Lifetime
- 1995-10-10 BR BR9509313A patent/BR9509313A/pt not_active IP Right Cessation
- 1995-10-10 DE DE69518084T patent/DE69518084T2/de not_active Expired - Lifetime
- 1995-10-10 DK DK95935151T patent/DK0777495T3/da active
- 1995-10-10 UA UA97052124A patent/UA42028C2/uk unknown
- 1995-10-10 NZ NZ294464A patent/NZ294464A/xx not_active IP Right Cessation
1997
- 1997-04-10 NO NO19971633A patent/NO320604B1/no not_active IP Right Cessation
- 1997-04-10 FI FI971486A patent/FI116558B/fi not_active IP Right Cessation
1998
- 1998-06-12 US US09/096,708 patent/US5935566A/en not_active Expired - Lifetime
2000
- 2000-10-13 GR GR20000402304T patent/GR3034619T3/el unknown
2005
- 2005-10-19 FI FI20055562A patent/FI117377B/fi not_active IP Right Cessation
2006
- 2006-04-20 JP JP2006117296A patent/JP2006193536A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
MX9702578A (es)	1997-07-31
US5766582A (en)	1998-06-16
JPH10506912A (ja)	1998-07-07
GR3034619T3 (en)	2001-01-31
SK43997A3 (en)	1997-10-08
ATE194774T1 (de)	2000-08-15
AU3727995A (en)	1996-05-02
JP2006193536A (ja)	2006-07-27
HK1008813A1 (en)	1999-05-21
KR100401401B1 (ko)	2004-02-18
NZ294464A (en)	1999-03-29
PT777495E (pt)	2000-12-29
EP0777495A1 (en)	1997-06-11
DE69531314T2 (de)	2004-05-13
AU708337B2 (en)	1999-08-05
ES2198830T3 (es)	2004-02-01
WO1996011018A1 (en)	1996-04-18
UA42028C2 (uk)	2001-10-15
SK282949B6 (sk)	2003-01-09
BR9509313A (pt)	1998-01-27
US5935566A (en)	1999-08-10
JP3978228B2 (ja)	2007-09-19
NO971633L (no)	1997-04-10
CN1102408C (zh)	2003-03-05
FI971486A0 (fi)	1997-04-10
FI20055562L (fi)	2005-10-19
DE69518084D1 (de)	2000-08-24
EP0970703B1 (en)	2003-07-16
DE69518084T2 (de)	2001-03-22
NO320604B1 (no)	2005-12-27
CA2201749C (en)	1999-06-15
CA2201749A1 (en)	1996-04-18
ES2148568T3 (es)	2000-10-16
KR970706017A (ko)	1997-11-03
FI117377B (fi)	2006-09-29
FI971486L (fi)	1997-04-10
CZ110497A3 (en)	1997-09-17
PL183797B1 (pl)	2002-07-31
HU225494B1 (en)	2007-01-29
ATE245033T1 (de)	2003-08-15
EP0777495B1 (en)	2000-07-19
RU2157236C2 (ru)	2000-10-10
CN1160355A (zh)	1997-09-24
PL319603A1 (en)	1997-08-18
FI116558B (fi)	2005-12-30
EP0970703A1 (en)	2000-01-12
CZ296961B6 (cs)	2006-08-16
HUT77287A (hu)	1998-03-30
DE69531314D1 (de)	2003-08-21
NO971633D0 (no)	1997-04-10

Publication	Publication Date	Title
DK0777495T3 (da)	2000-11-06	Stabile, vandige alfa-inteferonopløsningsformuleringer
NO308848B1 (no)	2000-11-06	Kromanforbindelse og farmasøytisk preparat som inneholder den
DK1172114T3 (da)	2005-01-24	Stabile koncentrerede insulinpræparater til pulmonær indgivelse
DK0731085T3 (da)	2000-04-17	Stilbenderivater og farmaceutiske sammensætinger indeholdende disse
EP0838221A4 (en)	2003-01-15	LYOPHILIZED HGF PREPARATIONS
DK0490549T3 (da)	1995-08-21	Stabilisering af calcitonin-holdige farmaceutiske præparater
ATE88697T1 (de)	1993-05-15	E-isomere von n alpha-(2-cyan-2-alkoximinoacetyl)-amino-s\|urederivaten und -peptiden.
BR0110290A (pt)	2003-02-18	Preparação lìquida estabilizada
DK0381617T3 (da)	1996-06-10	Desinfektions- og rensemiddel til kontaktlinser
NO20012817D0 (no)	2001-06-07	Phenethyl-5-bromopyridylthiourea (PBT) og dihydroalkoxybenzyloxopyrimidine (DABO) derivater som utöverspermicidal aktivitet
DE69423402D1 (de)	2000-04-20	Stabile, pharmazeutische Zusammensetzungen die hybrid alpha-Interferon enthalten
MX9305523A (es)	1994-04-29	Composiciones quimoterapeuticas mejoradas frente a infecciones microbianas en peces, la reparacion y uso de las mismas.
DK443988D0 (da)	1988-08-09	Injektionspraeparat indeholdende modificeret tpa
FR2718923B1 (fr)	1996-05-31	Composition désinfectante en solution aqueuse renfermant de l'orthophtalaldéhyde.
DK0506563T3 (da)	1995-05-15	Alginsyresuspension
SE9502927D0 (sv)	1995-08-24	Solution containing IGF-I
DE3863492D1 (de)	1991-08-08	Stabile 5-fluorouracil-formulierungen.
IT1247752B (it)	1994-12-30	Composizioni farmaceutiche aventi come principio attivo calcitonina da somministrarsi per via intranasale.